Driehaus Capital Management LLC Invests $843,000 in Codexis, Inc. (NASDAQ:CDXS)

Driehaus Capital Management LLC bought a new position in Codexis, Inc. (NASDAQ:CDXS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 176,748 shares of the biotechnology company's stock, valued at approximately $843,000. Driehaus Capital Management LLC owned approximately 0.22% of Codexis at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. Barclays PLC boosted its holdings in shares of Codexis by 51.1% during the third quarter. Barclays PLC now owns 207,628 shares of the biotechnology company's stock worth $640,000 after purchasing an additional 70,255 shares during the period. Tallon Kerry Patrick acquired a new stake in shares of Codexis during the fourth quarter worth approximately $2,018,000. Envestnet Asset Management Inc. boosted its holdings in shares of Codexis by 55.5% during the fourth quarter. Envestnet Asset Management Inc. now owns 309,713 shares of the biotechnology company's stock worth $1,477,000 after purchasing an additional 110,541 shares during the period. Inspire Investing LLC acquired a new stake in shares of Codexis during the fourth quarter worth approximately $405,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Codexis by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 1,855,514 shares of the biotechnology company's stock worth $8,853,000 after purchasing an additional 211,475 shares during the period. 78.54% of the stock is owned by hedge funds and other institutional investors.

Codexis Stock Down 3.5%

Shares of CDXS stock traded down $0.09 during trading on Wednesday, hitting $2.47. 658,833 shares of the company were exchanged, compared to its average volume of 655,842. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. The firm has a market capitalization of $204.63 million, a price-to-earnings ratio of -2.84 and a beta of 2.56. The business's 50-day simple moving average is $2.45 and its 200 day simple moving average is $3.75. Codexis, Inc. has a twelve month low of $1.90 and a twelve month high of $6.08.

Codexis (NASDAQ:CDXS - Get Free Report) last posted its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.05). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. As a group, analysts forecast that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.